CIBC Private Wealth Group LLC Acquires Shares of 206,717 Certara, Inc. (NASDAQ:CERT)

CIBC Private Wealth Group LLC bought a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 206,717 shares of the company’s stock, valued at approximately $2,278,000. CIBC Private Wealth Group LLC owned approximately 0.13% of Certara as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Venturi Wealth Management LLC boosted its position in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after buying an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its stake in Certara by 204.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after acquiring an additional 3,656 shares during the period. KBC Group NV increased its holdings in Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after acquiring an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after acquiring an additional 6,868 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Stock Performance

Shares of CERT stock opened at $10.23 on Thursday. The company has a market cap of $1.65 billion, a P/E ratio of -51.15, a PEG ratio of 9.29 and a beta of 1.60. The firm has a fifty day moving average price of $12.29 and a 200 day moving average price of $11.43. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18.

Analysts Set New Price Targets

Several analysts have recently issued reports on CERT shares. TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price on the stock. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Barclays lifted their price target on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.